FACTBOX — Major drugmakers turn to China for licensing deals

(Updates dateline, rewrites lede and adds Roche-Rona Therapeutics deal) Oct 13 (Reuters) — Rona Therapeutics said on Tuesday it has signed a licensing deal worth up to $1.16 billion with Swiss drugmaker Roche for an experimental obesity drug candidate. It is the latest in a wave of deals between Chinese biotech companies and global drugmakers. Chinese biotechs often retain domestic rights and license their drugs overseas in exchange for upfront and milestone payments as well as royalties. Some major deals are listed below: Date US-/EU-/ Chinese Deal Assets/pro Upfro Potentia UK-based company type grams nt l value company value Octobe Roche Rona Licens Experiment $100 Up to r 2026 Therapeu ing al RNAi milli $1.16 tics drug on billion targeting ALK7 for obesity and metabolic diseases Octobe Novartis Abogen Licens ABO2203, $575 Up to r 2026 ing experiment milli $7.8 al on billion RNA-based therapy for autoimmune conditions Septem Novo Jiangsu Licens HRS-1596, $300 Up to ber Nordisk Hengrui ing experiment milli $2.6 2026 uticals weight-los Septem Merck SciBrunc Licens SPR2015, $400 Up to ber h ing experiment milli $2.13 2026 Therapeu al cancer on billion tics drug Septem GSK HUTCHMED L